1. Introduction
NAFLD, fatty liver, weight gain, hypoglycemic, type 2 diabetes, diabetes
ADVERSE EVENTS, FATTY LIVER, CHRONIC DISEASES, INSULIN RESISTANCE, TYPE 2 DIABETES, DIABETES
As one of the most common chronic diseases, the prevalence rate of diabetes in China has skyrocketed, and the estimated prevalence of diabetes in Chinese adults is 11.6%, with type 2 diabetes predominating [Clinically, NAFLD is currently treated with multiple drugs, one of which is insulin sensitizer. Many literature reports that insulin sensitizers can effectively improve NAFLD [Therefore, the purpose of this study is to observe the therapeutic effect of pioglitazone-metformin combined treatment in type 2 diabetes patients with NAFLD. While using pioglitazone to improve the patient's liver histological performance, additional metformin can offset the risk of weight gain caused by pioglitazone. In addition, both can improve the patient's liver enzyme levels and insulin resistance, thereby increasing patient compliance, and bring obvious benefits to patients with type 2 diabetes and fatty liver.The hypoglycemic effect of pioglitazone hydrochloride and metformin hydrochloride tablets (15 mg pioglitazone/500 mg metformin) has been fully verified and affirmed. In this study, ultrasound liver fat content and liver enzyme levels were used as primary endpoint to evaluate the efficacy of NAFLD. In this multicenter clinical trial, we used a randomized, double-blind, double-simulated method, with metformin as the control group and ultrasound liver fat content and liver enzyme levels as the primary endpoints to evaluate the effect of combined treatment of metformin and pioglitazone in type 2 diabetes patients with NAFLD; the risk of adverse events is used to evaluate the safety of combined treatment of metformin and pioglitazone.